Lineage Cell Therapeutics, Inc. LCTX

Company Overview

Lineage Cell Therapeutics, Inc. is a U.S.-based biotechnology company focused on the development of allogeneic, or “off-the-shelf,” cell therapies derived from pluripotent stem cells. The company operates primarily within the regenerative medicine and biotechnology industries, with a concentration on ophthalmology, neurology, and auditory disorders. Its core strategy centers on using proprietary cell replacement technologies to address degenerative diseases where existing therapeutic options are limited or ineffective.

The company’s principal development programs have included retinal pigment epithelium cell therapy for geographic atrophy associated with age-related macular degeneration, oligodendrocyte progenitor cell therapy for spinal cord injury, and auditory neuron replacement programs for hearing loss. Revenue has historically been generated through collaboration agreements, licensing arrangements, grants, and investment income rather than large-scale commercial product sales, as most programs remain in clinical development stages. Originally founded as BioTime, Inc. in 1990, the company later rebranded as Lineage Cell Therapeutics to reflect its strategic shift toward focused clinical-stage cell therapy development and portfolio simplification.